<DOC>
	<DOCNO>NCT02468375</DOCNO>
	<brief_summary>The purpose study measure treatment satisfaction switch mirabegron patient Overactive Bladder ( OAB ) unsatisfied efficacy antimuscarinic therapy adverse event . Patient take mirabegron 50mg/day 12 week , satisfation therapy measure Treatment Satisfaction Questionnaire ( TSQ ) , Global Response Assessment ( GRA ) , OAB-q short form , OAB Symptom Score Willingness continue Questions .</brief_summary>
	<brief_title>Prospective Study Patient Perception Treatment Satisfaction After Switching Mirabegron Patients With Overactive Bladder Who Were Unsatisfied With Efficacy Antimuscarinic Therapy Adverse Event .</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Muscarinic Antagonists</mesh_term>
	<criteria>&lt; SCREENING &gt; 1. 20 year old , overactive bladder least 3 month . 2. total OABSS score 3 point , number 3 question score 2 point . 3. one criterion meet , 1 ) efficacy : unsatisfied antimuscarinics past 2 year . ( treat least 8 week ) 2 ) adverse event ( AE ) : unsatisfied antimuscarinics treatment due AE ( dry mouth , constipation , etc ) 4.subject write void diary . 5.subject understand study sign inform concent form . &lt; BASELINE &gt; Voiding Diary 3 day 1. micturition 8/day 2. urgency 2/day &lt; SCREENING &gt; 1. subject history risk acute urinary retension . 2. subject prostate cancer . 3. subject low urinary tract obstruction judge investigator subject appropriate participate study . 4. subject previous current bladder tumor . 5. subject significant stress incontinence mixed incontinence stress dominant factor . 6. prohibitied , permitted medication . 61. subject intake Alphablocker , Diabetes insipidus medication , PDE5 inhibitor ( BPH Tx ) , SSRI within 12weeks prior Screening . 62. subject start , stop change dose 5Alpha Reductase Inhibitors ( 5ARI ) within 4 week prior Screening . 63 . Subject currently intake Antimuscarinics , Antihistamines , Beta 2adrenoreceptor agonist , loop diuretic , CYP2D6 substrates narrow therapeutic index , CYP3A4 induce agent , CYP 3A4 inhibitor , Antifungal agent , Antiarrythmic drug . 7. subject Nondrug treatment include bladder training , pelvic floor muscle training within 12 week prior Screening . 8. subject severe hypertension define sit average systolic blood pressure 180 mmHg , and/or diastolic blood pressure 11 0mmHg . 9. pulse 100 bpm 50 bpm . 10. subject indwell catheter practice intermittent selfcatheterization . 11. subject surgery influence urinary track function ( ex , TURP , Laser treatment , etc. ) . 12. subject complication urinary tract infection , urinary stone , interstitial cystitis , recurrent UTI history . 13. subject know suspected hypersensitivity Beta 3 adrenalin receptor agonist . 14. subject clinically significant cardiovascular disease hepatic disease renal disease immunization diseases lung disease cancer . 15. subject plan pregnency , breast feed clinical trial period . &lt; BASELINE &gt; void volume 3000ml per day . post void residual volume 200ml</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>